Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Chinese biotech licensing deals have become a major source of global drug pipelines. Pharmaceutical Executive reported more than $43 billion in licensing commitments during the first five months of 2026, while US lawmakers proposed broader scrutiny of biotechnology investments linked
Learn how FDA device registration and listing connects with classification, product codes, 510(k) pathways, FURLS records, annual renewal, and inspection readiness. The guide also explains common data gaps that can delay imports or threaten U.S. market access.
A July 29, 2026 Pharmaceutical Technology feature by Christian Olsen examines a recurring failure in biologics R&D: systems preserve experimental results while losing the reasoning behind them. As candidates move from discovery into lead optimization, CMC and scale-up, missing context
GSK announced a £400 million plan on July 28, 2026, to establish a 300,000-square-foot global R&D centre on the Cambridge Biomedical Campus. The company plans to move more than 1,000 UK scientists to Cambridge, leave its Stevenage R&D site through
The FDA proposed a new registration pathway on July 10, 2026, for distributed manufacturing networks that operate through a hub-and-spoke model. If finalized, the FDA distributed manufacturing rule would let qualifying networks register as one establishment instead of registering every
This guide explains how manufacturers manage device classification, FDA listing, EU MDR conformity assessment, CE marking, UDI, EUDAMED, technical documentation, and post-market controls to reduce registration delays, inspection findings, and global market-access risks throughout the product lifecycle.
Argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion, placing a major bet on FB102 before its key Phase 2 celiac disease results arrive. The deal gives argenx a first-in-class anti-CD122 antibody with early signals in celiac disease
Explore how pharma ERP software supports batch tracking, expiry management, data integrity, audit trails, and computer system validation across pharmaceutical distribution. The article also explains implementation risks, inspection evidence, and why software alone cannot guarantee GMP or GDP compliance.